Iprivask

Iprivask is a brand name of desirudin, approved by the FDA in the following formulation(s):

IPRIVASK (desirudin recombinant - injectable; subcutaneous)

• 
  Manufacturer: CANYON
  
  Approval date: April 4, 2003
  
  Strength(s): 15MG/VIAL ^[RLD]

Has a generic version of Iprivask been approved?

No. There is currently no therapeutically equivalent version of Iprivask available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Iprivask. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Stable dry powders
  Patent 5,733,874
  Issued: March 31, 1998
  Inventor(s): Arvinte; Tudor
  Assignee(s): Novartis Corp.
  The present invention provides a freeze dried pharmaceutical composition comprising hirudin and a water-soluble salt of calcium and/or magnesium.
  
  Patent expiration dates:
  
  
  • March 31, 2015
    
  
  

See also...

• Iprivask Consumer Information (Wolters Kluwer)
• Iprivask Consumer Information (Cerner Multum)
• Iprivask Advanced Consumer Information (Micromedex)
• Iprivask AHFS DI Monographs (ASHP)
• Desirudin Consumer Information (Wolters Kluwer)
• Desirudin Consumer Information (Cerner Multum)
• Desirudin Subcutaneous Advanced Consumer Information (Micromedex)
• Desirudin AHFS DI Monographs (ASHP)